Curis Lifesciences accepted the resignation of Mr. Chand Rameshbhai Kanabar as Independent Director from its Board effective July 3, 2026, due to his pre-occupancy and increased professional commitments. The company confirmed that there are no other material reasons for his resignation beyond those stated in his letter. This change impacts the board composition as the pharmaceutical company moves forward with its governance structure.

Resignation Details

Mr. Kanabar formally tendered his resignation to the Board of Directors, citing his inability to continue owing to professional commitments. In his communication, he expressed appreciation for the cooperation and support received from the Board and management during his tenure. He confirmed that the reasons provided were exhaustive and no other material factors influenced his decision.

Regulatory Disclosures

The intimation was made to the National Stock Exchange of India in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the disclosure format. The Board will arrange to file the necessary forms and intimations with the Registrar of Companies and other concerned authorities.

Director's Other Roles

As per the disclosures, Mr. Kanabar holds directorships in other entities. He serves as an Independent Director at Accretion Pharmaceuticals Limited and Kian-M Export Limited, and as a Director at Golden Sparrow Consultancy Private Limited. His committee memberships include the Audit Committee, Nomination And Remuneration Committee, Stakeholder Relationship Committee, and Corporate Social Responsibility Committee at Accretion Pharmaceuticals Limited, and similar roles at Kian-M Export Limited.

Curis Lifesciences has been fined Rs 5,900 by the National Stock Exchange of India Limited (NSE) for delayed compliance with listing regulations for the year ended March 2026. The penalty, which includes GST, was imposed due to noncompliance with Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The intimation regarding the fine was received by the company via an email dated June 30, 2026. The communication cited a delay in compliance with the specific regulation and referenced the SEBI Master Circular issued on July 11, 2023. The company is required to pay the amount within 15 days from the date of the notice.

In its filing to the exchange, Curis Lifesciences stated that the financial impact of this development is limited to the fine amount. The disclosure was made in accordance with Regulation 30 of the SEBI Listing Regulations and a specific SEBI circular dated July 13, 2023.

The following table details the penalty information:

The confirmation of the details was provided by Jaimik Mansukhlal Patel, Director of Curis Lifesciences, in the regulatory filing submitted on July 1, 2026.